BioDelivery Sciences to Report Third Quarter 2018 Financial Results on November 8, 2018
Conference Call Dial In & Webcast Information:
|Date:||Thursday, November 8, 2018|
|Time:||4:30 PM Eastern Time|
Replays available through
BDSI's marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain, and opioid dependence. BDSI's headquarters is in
For more information, please visit or follow us:
BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) and BELBUCA® (buprenorphine) buccal film (CIII) are marketed in the U.S. by BioDelivery Sciences. For full prescribing information and important safety information on BDSI products please visit www.bdsi.com where the Company promptly posts press releases, SEC filings, and other important information or contact the Company at (800) 469-0261. For full prescribing and safety information on BELBUCA, please visit www.belbuca.com and for full prescribing and safety information on BUNAVAIL, please visit www.bunavail.com.
© 2018 BioDelivery Sciences International, Inc. All rights reserved.
Vice President, Investor & Public Relations
Source: BioDelivery Sciences International, Inc.